Board summary
Key figures
73,240
Registered population
61.1% aged 18–64
18.1%
Aged 65+
ICB 14.9% · England 17.9%
47.6%
In IMD quintile 1
ICB 40.7% · England 21.0%
~35,086
Core20 residents (est.)
Resident basis; registered basis ~34,826 · see page 3
12,880
Hypertension register
+3.84% in 3 yrs · England +5.60%
824
SMI register
35% of Tameside (LAD)'s
2,462
COPD register
Reviews -7.29% in 3 yrs
Forecast to 2030
14,418
Hypertension patients, 2030
+1,538 on today
66.8%
QRISK ≥20% on statins, 2030
-0.01pp over 3 yrs
4.9%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Respiratory annual reviews fall behind national trends.
Asthma reviews fell 3.5% to 62.5% (leaving about 2,100 unreviewed) and COPD reviews fell 7.3% to 70.0%, which may reflect recall capacity limits.
SMI physical health checks trail England.
SMI BMI recording fell 1.7 pp to 76.0% (England +5.1 pp) and BP recording is 81.7% (England 83.4%), which could reflect fragmented recall.
Recent blood pressure recording exceeds benchmarks.
Recent hypertension BP recording rose 5.7% to 91.0% (England 90.0%, Tameside 89.2%), with 82.6% control at age 80+ (England 81.2%).
Population, age and ethnicity
Hyde PCN serves 73,240 patients with an older age profile than the ICB
Hyde PCN cares for 73,240 registered patients across eight practices. Patients aged 65+ represent 18.1% of the list (13,265 patients; Tameside 16.4%, NHS Greater Manchester ICB 14.9%, England 17.9%). Children aged 0–17 make up 20.8% (15,207 patients; Tameside 21.3%, ICB 21.8%, England 19.6%), and 61.1% are aged 18–64 (44,768 patients; Tameside 62.3%, ICB 63.3%, England 62.7%). Census resident estimates record 0.1% Gypsy or Irish Traveller and 0.0% Roma. Projected list growth to 2030 is 1.9% (Tameside 1.4%, ICB 1.6%, England 2.3%) under unverified methodology.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Tameside (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Tameside LA) | 2,047 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.8% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.7% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Tameside LA) | 1,045 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Tameside LA) | 32.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation affects 47.6% of patients, spanning a 96.0 percentage point practice range
Across Hyde PCN, 47.6% of registered patients live in Core20 areas, above Tameside (40.9%), the ICB (40.7%) and England (21.0%), with an average IMD decile of 3.7 (England 5.5). Resident Core20 estimates total 35,086, while practice estimates sum to 34,826. Core20 share spans 96.0 pp across practices: Hattersley Group Practice records 96.0%, whereas The Smithy Surgery records 0.0%. In contrast, volume concentrates at The Brooke Surgery (10,255 estimated patients) and Haughton Thornley Medical Centres (6,680). Interventions could balance intensive practice targeting with PCN-wide cohort capacity.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
824
SMI register
1.11% recorded prevalence
528
Learning disability register
0.71% recorded prevalence
16
Care homes, 683 beds
In the PCN catchment
9.7%
Provide unpaid care
Tameside (LAD), Census 2021
Recorded severe mental illness prevalence is 1.1% (824 patients; Tameside 1.0%, ICB 1.1%, England 1.0%), and learning disability prevalence is 0.7% (528 patients; Tameside 0.7%, ICB 0.6%, England 0.6%). Catchment care homes total 16 sites with 683 beds, though resident registrations are unconfirmed.
Severe mental illness: physical health checks
Severe mental illness prevalence is 1.1% (England 1.0%). Over 2023 to 2025, annual BMI recording fell 1.7 pp to 76.0% (England +5.1 pp to 82.1%), alongside BP checks at 81.7% (England 83.4%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
12,880
Hypertension register
+3.84%
Register growth, 3 yrs
Tameside (LAD) +5.50% · England +5.60%
+3.24pp
BP control, under 80
≤140/90 · +3.10pp aged 80+
+1,538
More patients by 2030
Forecast 14,418 (18.77%)
Hypertension case-finding and control
Hypertension prevalence is 17.4% (12,880 patients), matching Tameside (17.4%) and above England (15.2%) and NHS Greater Manchester ICB (14.4%). Recent blood pressure recording reached 91.0%, above England (90.0%) and the ICB (90.3%). However, blood pressure control for patients aged under 80 is 67.0%, below England (67.8%) and the ICB (68.6%), while control at age 80+ reached 82.6% (England 81.2%). Denominators include personalised care adjustments, and observation periods are unconfirmed. Under-80 blood pressure control trails ICB and national benchmarks despite high monitoring rates, which may indicate medication titration or adherence gaps, testable by clinical audit.
Lipids and statins
For patients with QRISK ≥ 20%, lipid-lowering therapy uptake is 66.8% (England 63.6%, ICB 67.0%), but three-year change was -0.01% over 2023 to 2025 (England +6.2%). Stagnating uptake could reflect treatment-escalation gaps, testable via clinical audit.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 152,376 | £2.00 | £1.94 | £1.86 | £304,752 |
| Cardiovascular (all), 2025 | 215,510 | £3.09 | £3.15 | £3.33 | £665,926 |
Lipid-regulating drugs cost £2.00 per item across 152,376 items in 2026, compared with £1.86 in England, £1.94 in the ICB, and £2.01 in Tameside. Hyde PCN spends £21,333 more than at England's unit cost. This unit-cost indicator does not reflect prescribing efficiency or formulary appropriateness.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−3.45%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.31%
Asthma prevalence, PCN 3-yr % change
Recorded prevalence exceeds England for COPD (3.3%, 2,462 patients vs 1.9%) and asthma (8.2%, 5,714 patients vs 6.6%), alongside youth asthma prescribing (2,455 items per 1,000 aged 5–19 vs England 1,488). Over 2023 to 2025, COPD reviews fell 7.3% to 70.0% (England +2.8% to 76.4%) and asthma reviews fell 3.5% to 62.5% (England +4.4% to 65.7%), leaving about 2,100 unreviewed asthma patients. Falling reviews could reflect recall capacity constraints, unverified locally.
Cancer register and children's immunisation
Cancer register prevalence is 4.1% (3,032 patients; England 3.8%). In Q1 2025/26 childhood immunisations, 24-month 6-in-1 coverage reached 95.8% (England 92.2%). At age 5, coverage drops: MMR2 is 81.7% (11.2 pp below MMR1 at 92.9%, and 13.3 pp below the 95.0% target) and the 4-in-1 booster is 75.1% (England 80.9%). Strong infant uptake is not sustained into pre-school boosters.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
Cancer stage is published at ICB level, not at PCN level. In 2022, NHS Greater Manchester ICB recorded 55.6% of cancers diagnosed at stage 1 or 2 among cases with a known stage (6,491 of 11,679; England 55.3%), sitting 19.4 pp below the 75.0% national ambition by 2028, while 70.8% had a known stage (11,679 of 16,492). Closing this ICB gap would require about 2,270 extra early diagnoses annually. Within Hyde PCN, cervical screening (25-49) fell 3.2% over 2023 to 2025 (England -1.0%) to 67.8%, with 63.2% at Hattersley Group Practice. Proactive recall may improve screening uptake in practices where coverage trails the PCN average.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
Wait times describe trust and ICB performance, not PCN level. For urgent cancer pathways, Tameside and Glossop Integrated Care NHS Foundation Trust achieved 7.5 pp above the 75.0% 28-day faster diagnosis standard and 0.2 pp above the 96.0% 31-day combined treatment standard. However, on the 62-day referral to treatment standard (85.0%), the trust was 8.2 pp below standard. Across NHS Greater Manchester Integrated Care Board, the 62-day standard was 9.3 pp below standard, while the 28-day standard was 4.5 pp above standard.
| Pathways within standard (%) | Tameside and Glossop Integrated Care | Stockport | Manchester | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 82.48 | 83.21 | 80.06 | 79.53 | 79.32 |
| 31-day treatment (96%) | 96.25 | 97.39 | 92.54 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 76.77 | 74.67 | 72.85 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Tameside and Glossop Integrated Care | Stockport | Manchester | England |
|---|---|---|---|---|
| MRI | 0.00 | 1.41 | 11.68 | 21.40 |
| CT | 0.18 | 2.93 | 14.66 | 9.92 |
| Echocardiography | 0.00 | 17.46 | 4.91 | 28.48 |
| Colonoscopy | 1.51 | 5.53 | 4.51 | 30.83 |
| Gastroscopy | 5.45 | 5.31 | 29.35 | 29.02 |
| All 15 DM01 tests | 0.80 | 14.08 | 8.98 | 23.14 |
| Community services activity | Tameside residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 50,685 | 573,310 |
| Referrals | 9,450 | 94,470 |
| Patients with a contact | 15,790 | 183,535 |
Community services (residents of Tameside), Jun 2026 (provisional). In June 2026 (provisional), community services recorded 50,685 contacts for Tameside residents, of which 26,410 (52.1%) were with adults aged 65 and over. These borough-level data describe wider community caseloads and are not published at PCN level.
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Awburn House | 108 | 26.9 | 87.1% | 71.4% | 93.0% |
| Donneybrook | 106 | 52.9 | 51.1% | 78.6% | 79.4% |
| Haughton Thornley | 102 | 53.0 | 62.4% | 54.2% | 78.6% |
| The Smithy Surgery | 105 | 0.0 | 63.4% | 62.0% | 75.9% |
| Clarendon | 97 | 53.0 | 44.3% | 75.3% | 75.6% |
| Dukinfield | 115 | 34.4 | 68.0% | 64.3% | 75.5% |
| The Brooke Surgery | 90 | 50.7 | 45.5% | 56.8% | 64.4% |
| Hattersley | 96 | 96.0 | 36.5% | 78.5% | 49.6% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
15 of 25 tracked three-year trends trail England across Hyde PCN
Across 25 tracked three-year trends (2023 to 2025), 15 trail England. The widest lags are in learning disability prevalence, down 10.3% (England +5.4%), COPD annual reviews, down 7.3% (England +2.8%), asthma reviews, down 3.5% (England +4.4%), and severe mental illness BMI recording, down 1.7 pp (England +5.1 pp). Conversely, heart failure reviews grew 38.6% (England +8.7%), breast screening rose 13.8% (England +8.4%), and hypertension blood pressure recording increased 5.7% (England +3.6%). Slower review trajectories could reflect recall capacity limits, testable by template audit, unverified locally.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Learning disability register
COPD reviews
Asthma reviews
BMI record (SMI)
QRISK statin treatment
Heart failure reviews
Breast screening (53-70)
Hypertension BP reading
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Tameside (LAD) | Asset | PCN | Tameside (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 16 (683 beds) | n/a | Schools (catchment) | 83 | n/a |
| Children's centres | 7 | 16 | Places of worship | 47 | 104 |
| Libraries | 2 | 7 | Homelessness support (VCS) | 2 | 2 |
| Primary schools (LA maintained) | 10 | 22 | Primary academies | 25 | 46 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured respiratory annual review recall
Asthma reviews are 62.5% of 5,714 patients (England 65.7%, ICB 66.2%), down 3.5% over 2023 to 2025, leaving about 2,100 (2,142) unreviewed; COPD reviews fell 7.3% to 70.0% of 2,462 (England 76.4%). Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Bundled SMI physical health checks
Across 824 SMI patients (1.1% prevalence; 35% of Tameside's register), BMI recording is 76.0% (England 82.1%, ICB 82.9%; -6.1 pp vs England), with a 3-year change of -1.7 pp over 2023 to 2025 (England +5.1 pp), alcohol at 78.1% and BP at 81.7%. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Age-five booster and MMR2 catch-up
In Q1 2025/26 (cohort 197), age-5 4-in-1 coverage is 75.1% (England 80.9%), 19.9 pp below the 95.0% target; MMR2 is 81.7%, 11.2 pp below MMR1 (92.9%), with 19.7 pp gap at The Brooke Surgery. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult frailty capacity planning (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 resource allocation (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check template audit (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension blood pressure control review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster catch-up (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall review (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured respiratory annual review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Bundled SMI physical health checks (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Option 3 · Age-five booster and MMR2 catch-up (p12) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 · MMR dose 2 coverage at age 5 · MMR dose 1 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
